BioSpace News Archive

Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant of a non-qualified stock option and of restricted stock units as inducements material to the employee entering into employment with Voyager.

Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Board of Directors appointed Gerard Michel as Chief Executive Officer, effective October 1, 2020

Healthmap Solutions (Healthmap), a growing specialty Population Health Management (PHM) company with an industry-leading Kidney Health Management (KHM) program, today announced an expansion of the company’s executive leadership team in response to a year of unprecedented growth

ARKRAY USA , Inc., a leader in diabetes care products, announces the Company’s TechLITE Pen Needles are now indicated for use with pen injector devices for the subcutaneous injection of drugs. Previously, TechLITE Pen Needles were intended for the use of insulin only. “ARKRAY’s customers and the patients we serve will benefit from

Can N95 respirators be decontaminated in a steam sterilization cycle for reuse in situations of severe personal protective equipment shortage? That question has been explored through collaboration between a world-leading respirator manufacturer, 3M, and a global leader in sterilization solutions, Belimed.

SCS EXPERT is the first expandable percutaneous lead for neuromodulation treatment for chronic pain

IRLAB announced that the U.S. Food and Drug Administration has accepted IRLAB’s investigational new drug application for the drug candidate mesdopetam.

SyntheticMR announced that they have signed an agreement with GE Healthcare to integrate their quantitative MRI solution SyMRI in GE’s platform.

Debenture is secured against all of the assets of HydRx Farms Inc., a Whitby, Ontario research, cultivation, and extraction facility

Calliditas Therapeutics AB announced that the last visit of the 200th patient has taken place in Part A of the pivotal NeflgArd Phase 3 study